Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4952W HIGH $4.19
Volume
15.38 M
Value Traded
1.02 M
Short % Float
10.79%
-8.46%Week
+15.21%1 Month
+348.89%3 Month
+293.35%6 Month
-92.59%5 Year
-98.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
326.53 M
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
318.90 M
Total Shares
107.76 M
Float Shares
91.34 M
Insiders
15.24%
Institutions
13.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CYPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Cypherpunk Technologies Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cypherpunk Technologies Inc.
310Total events
4Upcoming
64Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
●Full ResultssirexatamabClinical Data
Publication of DeFianCe study results in Clinical Cancer Research
second-line metastatic colorectal cancersource ↗
▲Type C MeetingsirexatamabFDA Meeting
Type C meeting with FDA to discuss DeFianCe results and proposed registrational path
DKK1-high, second-line metastatic colorectal cancersource ↗
▲FDA Feedback ReceivedsirexatamabFDA Meeting
FDA alignment on Phase 3 trial design
DKK1-high, second-line metastatic colorectal cancersource ↗
●PublicationsirexatamabPresentation
Publication of DeFianCe study results in Clinical Cancer Research
Advanced colorectal adenocarcinomasource ↗
▼Primary Endpoint MissedsirexatamabClinical Data
DeFianCe study did not meet prespecified primary endpoint in intent-to-treat population
Advanced colorectal adenocarcinomasource ↗
◆Partnership / LicensesirexatamabCorporate
Strategic process initiated to advance sirexatamab
●Enrollment CompletesirexatamabTrial
DeFianCe study completed
advanced colorectal adenocarcinomasource ↗
▲Quarterly UpdateCorporate
3,023.13 ZEC generated in first weeks of mining operations (Aug 18-31, 2026)
▲Fast Track DesignationsirexatamabDesignation
FDA granted Fast Track designation to sirexatamab combination
DKK1-high metastatic colorectal cancersource ↗
▲Oral PresentationsirexatamabPresentation
Presented new plasma DKK1 biomarker assay and results from Part B of DeFianCe study at AACR 2026
colorectal cancersource ↗
◆Management ChangeCorporate
Appointed Khing Oei as Chairman of the Board and Will McEvoy as CIO and Board member
▲Full ResultssirexatamabClinical Data
Final results from Part B of DeFianCe study presented at ESMO 2025
microsatellite stable colorectal cancersource ↗
●Oral PresentationsirexatamabPresentation
Mini Oral presentation at ESMO Congress 2025
microsatellite stable colorectal cancersource ↗
◆Oral PresentationsirexatamabPresentation
Mini Oral Session at ESMO Congress 2025 presenting Phase 2 trial results
colorectal cancersource ↗
▼Equity OfferingCorporate
Leap Therapeutics announces $58.88M PIPE offering led by Winklevoss Capital
▲Oral PresentationsirexatamabPresentation
Presented final clinical data from Part B of DeFianCe study at ESMO Congress
colorectal cancersource ↗
▲Full ResultssirexatamabClinical Data
Final results from Part B of DeFianCe study presented
colorectal cancersource ↗
◆Pipeline PrioritizationCorporate
Board initiated process to explore strategic alternatives to maximize shareholder value
◆Full ResultssirexatamabClinical Data
Reported updated data from Part B of Phase 2 DeFianCe study
second-line colorectal cancersource ↗
◆Timing GuidancePresentation
Intend to provide further update on strategic alternatives in coming weeks
▲Enrollment CompletesirexatamabTrial
Completed patient treatment in DeFianCe trial of sirexatamab plus bevacizumab and chemotherapy
second-line colorectal cancersource ↗
▲Full ResultssirexatamabClinical Data
Updated results from Part B of DeFianCe study showing statistically significant PFS improvements in subgroups
colorectal cancersource ↗
▼Trial DiscontinuedsirexatamabTrial
Decision to wind-down DeFianCe clinical trial
colorectal cancersource ↗
◆AcquisitionCorporate
Initiated process to explore strategic alternatives including potential sale or partnership for sirexatamab and FL-501
◆Topline ReadoutDKN-01Clinical Data
Data expected from Part B of DeFianCe study
advanced colorectal cancer (CRC)source ↗
◆Topline ReadoutsirexatamabClinical Data
Upcoming data updates from DeFianCe study this quarter
colorectal cancersource ↗
◆Topline ReadoutDKN-01Clinical Data
Initial data from Part B, including left-sided CRC subpopulation, expected mid 2025
advanced colorectal cancersource ↗
▲Runway Guidance UpdateCorporate
Combined cash runway expected to fund operations to mid-2025
●Enrollment UpdatesirexatamabTrial
42 patients remain on study drug in DeFianCe (25 sirexatamab, 17 control)
colorectal cancersource ↗
◆Oral PresentationsirexatamabPresentation
Conference call to present updated CRC clinical data from Part B of DeFianCe study
colorectal cancersource ↗
▲Topline ReadoutsirexatamabClinical Data
Updated data from Part B of DeFianCe study announced
colorectal cancersource ↗
◆Partnership / LicensesirexatamabCorporate
Engaged financial advisor to explore business development opportunities for sirexatamab
colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How CYPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$18M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 69%
Micro Cap(rank 454 of 658)
Percentile Rank
Cypherpunk Technologies Inc. faces pipeline headwinds (30/100), with $650M risk-adjusted pipeline value, led by DKN-01 in Multiple Myeloma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DKN-01 Small moleculeCompletedNCT05480306 | Colorectal Cancer | Phase 2 | COMPLETED | 188 | Jul 10, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every CYPH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sirexatamab Fast Track | metastatic colorectal cancer | Phase 2 | 2026-08-12 | 188 patients; sirexatamab improved response, progression-free survival, and overall survival; baseline plasma DKK1 identifies patients with more aggressive disease; patients with high DKK1 do worse on standard of care; patients who gained the most in response and survival when sirexatamab was addedRead More | Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from ...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Oei Khing DjienDirector | Sell | -168,750 | $3.92 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CYPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CYPH for Q2 2026. | ||||
CYPH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CYPH ranks across every disease it competes in
Competitive Position is a premium feature
See how CYPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCYPH News
CYPH▲ +9.7%on this news· ran to +21% by day 3
Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors
Cypherpunk Technologies has appointed Amanda Fabiano to its Board of Directors. Fabiano, a veteran in digital asset mining, aims to leverage her expertise to enhance Cypherpunk's operations. The company recently launched its mining fleet, generating over 3,000 ZEC in rewards shortly after its inception. This strategic move is part of Cypherpunk's mission to advance privacy technologies.
Read more →CYPH▲ +14.2%on this news· ran to +101% by day 3
Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet
Cypherpunk Technologies has launched Cypherpunk Mining, now the largest Zcash mining fleet globally, through a $33.33 million deal with Winklevoss Capital. The fleet, representing 18% of the Zcash network, enhances the company's exposure to Zcash mining and treasury growth. Kevin Zhang joins as Head of Mining, bringing extensive experience to the team.
Read more →CYPHLeap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
Leap Therapeutics published results from the Phase 2 DeFianCe study of sirexatamab, showing its efficacy in DKK1-high metastatic colorectal cancer (mCRC) patients. The study found that higher baseline plasma DKK1 levels correlate with better treatment responses and survival outcomes when sirexatamab is added to standard therapies. Despite not meeting the primary endpoint in the overall population, the findings support the potential for a biomarker-selected Phase 3 trial.
Read more →CYPHCypherpunk Technologies Reports Second Quarter 2026 Financial Results
Cypherpunk Technologies reported a strong financial performance for Q2 2026, achieving a net income of $39.4 million, largely due to an unrealized gain from Zcash holdings. The company also announced FDA alignment for a Phase 3 trial of sirexatamab in DKK1-high metastatic colorectal cancer. Additionally, Dev Ojha was appointed as an advisor, enhancing the company's strategic direction.
Read more →CYPH▲ +15.4%on this news
Cypherpunk Technologies Reports First Quarter 2026 Financial Results
Cypherpunk Technologies reported its financial results for Q1 2026, highlighting a significant increase in Zcash holdings and the Fast Track designation for sirexatamab by the FDA. The company faced a net loss of $77.2 million, primarily due to unrealized losses on ZEC holdings. Despite these challenges, Cypherpunk is advancing its privacy technology mission and launched a new investor dashboard.
Read more →CYPH▼ -5.3%on this news
Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard
Cypherpunk Technologies Inc. has announced the purchase of 9,163.32 ZEC for $2,150,000, increasing its total ZEC holdings to 303,906.40. The company has also launched a new website and investor dashboard to improve transparency and communication with shareholders. Future updates regarding ZEC acquisitions will be communicated through digital channels.
Read more →CYPH▲ +21.5%on this news· ran to +37% by day 1
Cypherpunk Reports Full Year 2025 Financial Results
Cypherpunk Technologies Inc. reported its financial results for 2025, highlighting a transformational year with a net income of $4.8 million, a significant turnaround from a loss in 2024. The company raised $58.88 million to focus on privacy technologies and made strategic investments in Zcash. Additionally, its subsidiary Leap Therapeutics presented promising data on sirexatamab for colorectal cancer treatment, indicating a positive outlook for future developments.
Read more →CYPH▲ +5.7%on this news· ran to +17% by day 3
Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)
Cypherpunk Technologies Inc. has announced a $5 million investment in the Zcash Open Development Lab (ZODL), marking its first investment outside of ZEC. This investment aligns with Cypherpunk's mission to advance privacy technologies and aims to improve the usability of Zcash through continued development of the Zashi wallet. The partnership is expected to enhance the adoption of Zcash as a private digital currency.
Read more →CYPHCypherpunk Adds Arjun Khemani as Strategic Advisor
Cypherpunk Technologies Inc. has appointed Arjun Khemani as a Strategic Advisor to enhance its privacy technology initiatives. Khemani, known for his contributions to the Zcash ecosystem, will provide guidance on privacy adoption and digital self-sovereignty. His appointment follows the addition of other notable advisors, reflecting Cypherpunk's commitment to advancing privacy-preserving technologies.
Read more →CYPH▲ +11%on this news
Cypherpunk Accelerates Zcash Accumulation; Increa ses Treasury Holdings to 290,062.67 ZEC Cambridge, Mass.
Cypherpunk Technologies Inc. announced an expansion of its treasury by acquiring an additional 56,418.09 ZEC, bringing its total holdings to 290,062.67 ZEC. This acquisition positions the company to accumulate 5% of the Zcash network, reflecting a strategic commitment to privacy-focused technologies. The new additions to their treasury represent a significant investment of approximately $29 million at an average price of $514.02 per ZEC. Additionally, the company plans to continue branching into various privacy-preserving initiatives through its subsidiary Leap Therapeutics.
Read more →CYPH▲ +11%on this news
Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC
Cypherpunk Technologies Inc. has expanded its treasury by acquiring an additional 56,418.09 ZEC for approximately $29 million, raising its total Zcash holdings to 290,062.67 ZEC. The company aims to accumulate 5% of the Zcash network, positioning itself favorably in the privacy technology market. This acquisition reflects Cypherpunk's commitment to enhancing its digital asset strategy.
Read more →CYPH▲ +39%on this news
Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor
Cypherpunk Technologies Inc. has appointed Josh Swihart, CEO of Electric Coin Company, as a Strategic Advisor. Swihart will provide insights on Zcash ecosystem dynamics and support the company's commitment to privacy-enhancing technologies. This appointment follows Cypherpunk's rebranding and significant investments in Zcash, reflecting its dedication to privacy and economic freedom.
Read more →CYPH▲ +39.7%on this news
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
Cypherpunk Technologies Inc. has appointed Zooko Wilcox, the founder of Zcash, as a Strategic Advisor. His extensive experience in cryptography and digital asset governance is expected to guide the company's future initiatives. Cypherpunk aims to enhance its Zcash treasury and support privacy innovations, emphasizing the importance of user-controlled privacy in society.
Read more →CYPH▲ +22.2%on this news
C ypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% Cambridge, Mass.
Cypherpunk Technologies Inc. has announced an additional purchase of $18 million worth of ZEC, increasing its total holdings to 233,644.56 ZEC and owning 1.43% of the network. This acquisition follows an earlier purchase of over $50 million in ZEC, reflecting the company's commitment to digital privacy assets. The recent addition of seasoned investors to its Board aims to bolster the company's strategy in both digital asset acquisition and the development of cancer therapies. Overall, Cypherpunk seeks to enhance shareholder value through its diversified focus on privacy and healthcare.
Read more →CYPH▲ +22.2%on this news
Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43%
Cypherpunk Technologies Inc. has announced the purchase of an additional 29,869.29 ZEC for $18 million, raising its total ZEC holdings to 233,644.56. This acquisition brings the company's total network ownership to 1.43%. The company emphasizes the importance of privacy in a digital world and has appointed new board members to strengthen its leadership.
Read more →CYPHLeap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cy
Leap Therapeutics, now rebranded as Cypherpunk Technologies Inc., is shifting its focus towards accumulating Zcash (ZEC) as part of a new digital asset treasury strategy. The company has announced the acquisition of 203,775.27 ZEC and plans to change its ticker symbol to CYPH. Khing Oei and Will McEvoy have been appointed to the Board of Directors, signaling a commitment to enhancing shareholder value through active participation in the evolving Zcash market. This strategic pivot comes after a successful $58.88 million private placement led by Winklevoss Capital.
Read more →CYPHCypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Cypherpunk Technologies Inc., formerly Leap Therapeutics, reported its Q3 2025 financial results, highlighting a name change to emphasize its focus on digital assets. The company raised $58.88 million to support its digital asset treasury strategy and presented positive Phase 2 trial results for its cancer treatment, sirexatamab. Despite a net loss, the company is optimistic about its future direction in both drug development and digital asset investments.
Read more →CYPHLeap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS,
Leap Therapeutics announced positive final results from the DeFianCe study, demonstrating that sirexatamab significantly improves progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients with high levels of DKK1. Presented at the ESMO Congress 2025, these findings support the potential of sirexatamab in enhancing treatment options for patients who have limited alternative therapies. The company aims to move forward with a registrational trial and optimize diagnostic testing for DKK1 levels to identify suitable patients. Leap Therapeutics remains focused on developing targeted therapies for complex cancers.
Read more →CYPHLeap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy Cambridge, MA
Leap Therapeutics has successfully closed a private placement raising $58.88 million, led by Winklevoss Capital to begin a digital asset treasury strategy. The transaction involves the issuance of shares, pre-funded warrants, and additional warrants. The investment aims to contribute to Leap's ongoing therapeutic programs while leveraging Winklevoss Capital's expertise in digital assets. This partnership also includes the expansion of Leap's Board of Directors to include nominees from Winklevoss Capital.
Read more →About Cypherpunk Technologies Inc.
Headquarters47 THORNDIKE STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next CYPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime